Nanox Imaging Ltd. (NASDAQ: NNOX) has taken a significant step in expanding the reach of its AI-driven healthcare solutions by signing an exclusive reseller agreement for its bone health product, HealthOST, in the United Kingdom. The agreement, announced through a press release, grants Vertec Scientific Ltd. the exclusive rights to market and sell HealthOST in the UK for an initial three-year term, subject to minimum annual license commitments. This move underscores the growing adoption of AI-based diagnostic tools in clinical practice and highlights the importance of early detection in managing chronic diseases.
HealthOST is an FDA-cleared and UKCA/CE-marked AI software solution designed to analyze routine CT scans to help clinicians evaluate musculoskeletal diseases of the spine, particularly osteoporosis. Osteoporosis is a condition that weakens bones, making them fragile and more prone to fractures. It is often undiagnosed until a fracture occurs, making early detection critical. By leveraging AI to identify signs of bone disease in scans that are already being performed for other reasons, HealthOST enables opportunistic screening without additional radiation exposure or patient visits.
The significance of this agreement is amplified by the recent recommendation from the National Institute for Health and Care Excellence (NICE). In November 2025, NICE recommended HealthOST and a previous version, HealthVCF, among five AI technologies for use in the National Health Service (NHS) to aid in the opportunistic detection of vertebral fragility fractures. These fractures are a common complication of osteoporosis and often go unnoticed. NICE's endorsement is a strong validation of the clinical utility and cost-effectiveness of AI-powered tools in routine healthcare settings.
For the UK healthcare system, the availability of HealthOST through Vertec Scientific could lead to earlier diagnosis and intervention for osteoporosis, potentially reducing the burden of fractures on patients and the NHS. The NHS has long been challenged with the rising costs of fracture treatment, which are estimated to be in the billions annually. By catching bone disease earlier, AI tools like HealthOST can help mitigate these costs and improve patient outcomes.
Nanox's broader strategy is to drive the world's transition to preventive healthcare by delivering an integrated medical imaging and healthcare services platform. The company combines affordable imaging hardware, advanced AI-based solutions, cloud-based software, and remote radiology services to enable earlier detection and broader access to care. The HealthOST agreement is a testament to this vision, as it brings AI-powered diagnostics into mainstream clinical workflows.
Vertec Scientific, a UK-based company with expertise in medical equipment distribution, is well-positioned to commercialize HealthOST across the UK. The exclusive agreement ensures that Vertec will focus its efforts on maximizing the product's reach and adoption, subject to performance commitments.
For investors and the healthcare industry, this announcement signals a growing trend of AI integration in radiology and preventive medicine. It also demonstrates Nanox's ability to secure strategic partnerships that expand its global footprint. As AI continues to gain traction in medical diagnostics, agreements like this are likely to become more common, reshaping how diseases are detected and managed.
In summary, the exclusive UK reseller agreement for HealthOST represents a major milestone for Nanox AI and the broader adoption of AI in healthcare. With NICE's recommendation and the support of a dedicated reseller, HealthOST has the potential to significantly impact osteoporosis detection and management in the UK, ultimately improving patient lives and reducing healthcare costs.
